Loading...
Loading...
KMPH| Name | Value |
|---|---|
| Revenues | 2.9M |
| Cost of Revenue | 0.1M |
| Gross Profit | 2.8M |
| Operating Expense | 15.7M |
| Operating I/L | -12.1M |
| Other Income/Expense | 0.2M |
| Interest Income | 0.0M |
| Pretax | -11.9M |
| Income Tax Expense | -11.9M |
| Net Income/Loss | -0.0M |
KemPharm, Inc. is a specialty pharmaceutical company that focuses on discovering and developing proprietary prodrugs to treat serious medical conditions. The company's revenue is generated through the development and commercialization of prodrug product candidates, including AZSTARYS for attention deficit hyperactivity disorder and APADAZ for pain management. KemPharm's pipeline includes prodrug versions of existing compounds for conditions such as attention deficit hyperactivity disorder, stimulant use disorder, and CNS rare diseases. The company also engages in collaboration and license agreements to further develop and commercialize its prodrug products.
